{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:09:15Z","timestamp":1791925755940,"version":"4.3.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,25]]},"DOI":"10.7759\/cureus.61048","type":"journal-article","created":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T11:56:11Z","timestamp":1716638171000},"source":"Crossref","is-referenced-by-count":4,"title":["Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study"],"prefix":"10.7759","author":[{"given":"Ryohei","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Ohsaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, et al.. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021, 384:403-16. 10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, et al.. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020, 383:2603-15. 10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie ZG","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021, 21:855. 10.1186\/s12879-021-06536-3","journal-title":"BMC Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area","volume":"323","author":"Richardson S","year":"2020","unstructured":"Richardson S, Hirsch JS, Narasimhan M, et al.. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020, 323:2052-9. 10.1001\/jama.2020.6775","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0485-2","article-title":"COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study","volume":"43","author":"Huang S","year":"2020","unstructured":"Huang S, Wang J, Liu F, et al.. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res. 2020, 43:824-31. 10.1038\/s41440-020-0485-2","journal-title":"Hypertens Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01586-0","article-title":"Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study","volume":"400","author":"Wong CK","year":"2022","unstructured":"Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022, 400:1213-22. 10.1016\/S0140-6736(22)01586-0","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results","volume":"384","author":"Pan H","year":"2021","unstructured":"Pan H, Peto R, Henao-Restrepo AM, et al.. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021, 384:497-511. 10.1056\/NEJMoa2023184","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li G","year":"2023","unstructured":"Li G, Hilgenfeld R, Whitley R, De Clercq E. Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov. 2023, 22:449-75. 10.1038\/s41573-023-00672-y","journal-title":"Nat Rev Drug Discov"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19 - Final Report","volume":"383","author":"Beigel JH","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al.. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020, 383:1813-26. 10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Jayk Bernal A","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al.. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022, 386:509-20. 10.1056\/NEJMoa2116044","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac933","article-title":"Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study","volume":"76","author":"Mukae H","year":"2023","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al.. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2\/3 Study. Clin Infect Dis. 2023, 76:1403-11. 10.1093\/cid\/ciac933","journal-title":"Clin Infect Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00278-0","article-title":"The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era","volume":"3","author":"Fan H","year":"2022","unstructured":"Fan H, Lou F, Fan J, Li M, Tong Y. The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era. Lancet Microbe. 2022, 3:e91. 10.1016\/S2666-5247(21)00278-0","journal-title":"Lancet Microbe"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00697-22","article-title":"A Randomized Phase 2\/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part","volume":"66","author":"Mukae H","year":"2022","unstructured":"Mukae H, Yotsuyanagi H, Ohmagari N, et al.. A Randomized Phase 2\/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. Antimicrob Agents Chemother. 2022, 66:e0069722. 10.1128\/aac.00697-22","journal-title":"Antimicrob Agents Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac257","article-title":"Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model","volume":"77","author":"Nobori H","year":"2022","unstructured":"Nobori H, Fukao K, Kuroda T, et al.. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model. J Antimicrob Chemother. 2022, 77:2984-91. 10.1093\/jac\/dkac257","journal-title":"J Antimicrob Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2023.09.020","article-title":"Seroprevalence kinetics of SARS-CoV-2 antibodies in pediatric patients visiting a hospital during COVID-19 pandemic in Japan","volume":"30","author":"Hashimoto T","year":"2024","unstructured":"Hashimoto T, Yahiro T, Khan S, et al.. Seroprevalence kinetics of SARS-CoV-2 antibodies in pediatric patients visiting a hospital during COVID-19 pandemic in Japan. J Infect Chemother. 2024, 30:169-71. 10.1016\/j.jiac.2023.09.020","journal-title":"J Infect Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2020.07.014","article-title":"COVID-19 and comorbidities: Deleterious impact on infected patients","volume":"13","author":"Ejaz H","year":"2020","unstructured":"Ejaz H, Alsrhani A, Zafar A, et al.. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020, 13:1833-9. 10.1016\/j.jiph.2020.07.014","journal-title":"J Infect Public Health"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101205","article-title":"Aging in COVID-19: Vulnerability, immunity and intervention","volume":"65","author":"Chen Y","year":"2021","unstructured":"Chen Y, Klein SL, Garibaldi BT, et al.. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev. 2021, 65:101205. 10.1016\/j.arr.2020.101205","journal-title":"Ageing Res Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial","volume":"7","author":"Yotsuyanagi H","year":"2024","unstructured":"Yotsuyanagi H, Ohmagari N, Doi Y, et al.. Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. JAMA Netw Open. 2024, 7:e2354991. 10.1001\/jamanetworkopen.2023.54991","journal-title":"JAMA Netw Open"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/242222-real-world-efficacy-of-ensitrelvir-in-hospitalized-patients-with-covid-19-in-japan-a-retrospective-observational-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T11:56:14Z","timestamp":1716638174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/242222-real-world-efficacy-of-ensitrelvir-in-hospitalized-patients-with-covid-19-in-japan-a-retrospective-observational-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,25]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.61048","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,25]]}}}